Spruce Biosciences, Inc. (SPRB)
| Market Cap | 58.81M |
| Revenue (ttm) | 697,000 |
| Net Income (ttm) | -47.88M |
| Shares Out | 1.07M |
| EPS (ttm) | -82.48 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,600 |
| Open | 59.27 |
| Previous Close | 58.55 |
| Day's Range | 54.94 - 59.34 |
| 52-Week Range | 4.28 - 240.00 |
| Beta | 3.61 |
| Analysts | Buy |
| Price Target | 187.90 (+242.01%) |
| Earnings Date | Apr 14, 2026 |
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, including anhedonia, weight alterations, and altered sle... [Read more]
Financial Performance
In 2024, Spruce Biosciences's revenue was $4.91 million, a decrease of -51.32% compared to the previous year's $10.09 million. Losses were -$53.04 million, 10.7% more than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for SPRB stock is "Buy." The 12-month stock price target is $187.9, which is an increase of 242.01% from the latest price.
News
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy's Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 18, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of nove...
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Spruce) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neu...
Spruce Biosciences Appoints Proven Pharmaceutical Commercial Leader Keli Walbert to Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)
Spruce Biosciences received FDA Breakthrough Therapy Designation for TA-ERT in treating San Filippo Syndrome Type B [MPS IIIB]. BTD enables potential rolling BLA submission, Priority Review, and Accel...
This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.
The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological...